Bullish Case: MEDP just beat Q3 with all metrics above consensus and 2026 guidance raised—Leerink saw 'no holes'—yet the stock only slipped ~1% post-print, showing sellers were absorbed at $650+. Helium's density peaks near $670-680 with density rising through $660, term structure is in contango (front ~22-32% vs 42-46% back), and net bullish risk is 28% above bearish. Post-earnings IV compression with flat price action favors drift higher toward the $670-700 density shoulder.

Bearish Case: The Oct 21 beat-and-raise was sold—'sell the news' on a crowded winner up 11.5% YoY at 6.1x book. CEO Troendle sold another $1.59M Oct 25 after $70M+ September sales with no insider buying. Volume is at the 1st percentile with 1743% more put flow—smart-money distribution signature. If Q4 bookings soften, the $560-620 zone (thin Helium density) offers little support.

Potential Outcomes:

1. Post-earnings drift up (32%): Beat absorbed; $660-680 range, IV grinds down as market PDF mass sits at $670-680.
2. Chop/mean-revert (30%): Flat $630-670; 1st-percentile volume signals no conviction; Helium +1.48% forecast.
3. Insider/valuation unwind (22%): Continued Troendle sales compress multiple; -8-12% toward $580-600 where market density bulges.
4. Macro shock (16%): SPY -5% week (SPY surface shows fat downside wing); MEDP -12-18% on high-beta CRO de-rating.

October 31, 2026